Innate triggering and antiviral effector functions of activin A

5A:2^dCt <i>GAPDH-INHBA</i> expression following transfection of human PBMC (peripheral blood mononuclear cells) with IVT-RNA or poly(I:C) at two doses<br><br>5B:2^dCt <i>GAPDH-MX1</i> expression following transfection of human PBMC with IVT-RNA or poly(I:C) at two doses<br>5C:2^dCt <i>GAPDH-IFI6</i> expression following transfection of human PBMC with IVT-RNA or poly(I:C) at two doses<br>5D:2^dCt <i>GAPDH-INHBA</i> expression following exposure of human PBMC to the imidazoquinolones R848 and R837<br>5E:2^dCt <i>GAPDH-MX1</i> expression following exposure of human PBMC to the imidazoquinolones R848 and R837<br>5F:2^dCt <i>GAPDH-INHBA</i> expression following transfection of human PBMC with ssRNA40 LyoVec (TLR8 agonist)<br><br>5G:2^dCt <i>GAPDH-IFI6</i> expression following transfection of human PBMC with ssRNA40 LyoVec (TLR8 agonist)<br>6A:2^dCt <i>GAPDH-INHBA</i> at 48 hours post-infection in A549.gfp cells infected with increasing titres of Sendai virus (SeV) compared to controls<br>6B:2^dCt <i>GAPDH-MX1</i> at 48 hours post-infection in A549.gfp cells infected with increasing titres of Sendai virus (SeV) compared to controls<br>6C:2^dCt <i>GAPDH-INHBA </i>expression in HuH7 (RIG-I replete) versus HuH7.5 (RIG-I deficient) cells following SeV infection at various multiplicities, assayed at 48 hours post-infection.<br>6D:2^dCt <i>GAPDH-MX1 </i>expression in HuH7 (RIG-I replete) versus HuH7.5 (RIG-I deficient) cells following SeV infection at various multiplicities, assayed at 48 hours post-infection.<br>6E:2^dCt <i>GAPDH-SEV </i>(encoding Sendai virus genomic RNA) expression in HuH7 and HuH7.5 cell lines, assayed at 48 hours post-infection<br>6F:Fold change in <i>INHBA</i> expression, normalized to <i>GAPDH</i>, at 72 hours post-infection in HuH7.5.1 cells relative to uninfected (U.I.) cells.<br>Figure 6G:Fold change in <i>MX1</i> expression, normalized to <i>GAPDH</i>, at 72 hours post-infection in HuH7.5.1 cells relative to uninfected (U.I.) cells.<br>7A:2^dCt <i>Hprt-Inhba</i> expression in the lungs of FLUAV PR/8 infected mice at 72 hours post-infection.<br>p { margin-bottom: 0.25cm; direction: ltr; color: #000000; line-height: 115%; text-align: left; orphans: 2; widows: 2; background: transparent }p.western { font-family: "Liberation Serif", serif; font-size: 12pt; so-language: en-GB }p.cjk { font-family: "Noto Serif CJK SC"; font-size: 12pt; so-language: zh-CN }p.ctl { font-family: "FreeSans"; font-size: 12pt; so-language: hi-IN }<br>7B:2^dCt <i>Hprt-Isg15</i> expression in the lungs of FLUAV PR/8 infected mice at 72 hours post-infection.<br><br>7C:Correlation of <i>Inhba</i> and <i>Isg15</i> transcript induction in the lungs of FLUAV PR/8 infected mice at 72 hours post-infection (linear regression, R² = 0.9271, p=0.002)<br>7D:2^dCt <i>Hprt-Inhba</i> expression in the liver of FLUAV PR/8 infected mice at 72 hours post-infection<br><br>7E:2^dCt <i>Hprt-Isg15</i> expression in the liver of FLUAV PR/8 infected mice at 72 hours post-infection<br>7F:2^dCt <i>Hprt-Inhba</i> induction in the lung tissue of FLUAV PR/8 infected mice at 48 hours post-infection, across a range of increasing multiplicities of infection.<br><br> 7G:2^dCt <i>Hprt-Inhba</i> expression in wildtype or MAVS-depleted mice at 48 hours post-infection with FLUAV PR/8<br>7H:2^dCt <i>Hprt-Isg15</i> expression in wildtype of MAVS-depleted mice at 48 hours post-infection with FLUAV PR/8<br>Supplementary Figure 1A:Fold change <i>INHBA</i> normalized to <i>GAPDH</i> for HuH7 cells exposed to recombinant IFN or control medium (D10)<br>Supplementary Figure 1B/C/D: OR6 cells incubated with a titration of IFNα in the presence of titrating doses of activin A; assayed for Renilla luciferse and Cell Titer Glo activity.<br>

5A: 以2^dCt值表征的<i>GAPDH-INHBA</i>表达水平，对应将体外转录RNA（IVT-RNA）或聚肌胞苷酸（poly(I:C)）以两种剂量转染人外周血单个核细胞（peripheral blood mononuclear cells，PBMC）后的检测结果。

5B: 以2^dCt值表征的<i>GAPDH-MX1</i>表达水平，对应将IVT-RNA或poly(I:C)以两种剂量转染人PBMC后的检测结果。
5C: 以2^dCt值表征的<i>GAPDH-IFI6</i>表达水平，对应将IVT-RNA或poly(I:C)以两种剂量转染人PBMC后的检测结果。
5D: 以2^dCt值表征的<i>GAPDH-INHBA</i>表达水平，对应人PBMC暴露于咪唑并喹啉类化合物R848与R837后的检测结果。
5E: 以2^dCt值表征的<i>GAPDH-MX1</i>表达水平，对应人PBMC暴露于咪唑并喹啉类化合物R848与R837后的检测结果。
5F: 以2^dCt值表征的<i>GAPDH-INHBA</i>表达水平，对应将ssRNA40 LyoVec（Toll样受体8（TLR8）激动剂）转染人PBMC后的检测结果。

5G: 以2^dCt值表征的<i>GAPDH-IFI6</i>表达水平，对应将ssRNA40 LyoVec（TLR8激动剂）转染人PBMC后的检测结果。
6A: 以2^dCt值表征的<i>GAPDH-INHBA</i>表达水平，为感染后48小时的A549.gfp细胞的检测结果，该细胞以递增滴度的仙台病毒（Sendai virus，SeV）感染，并设置对照组进行对比。
6B: 以2^dCt值表征的<i>GAPDH-MX1</i>表达水平，为感染后48小时的A549.gfp细胞的检测结果，该细胞以递增滴度的SeV感染，并设置对照组进行对比。
6C: 以2^dCt值表征的<i>GAPDH-INHBA</i>表达水平，对比了HuH7（维甲酸诱导基因I（RIG-I）充足型）与HuH7.5（RIG-I缺陷型）细胞在不同感染复数下经SeV感染后的表达情况，于感染后48小时完成检测。
6D: 以2^dCt值表征的<i>GAPDH-MX1</i>表达水平，对比了HuH7（RIG-I充足型）与HuH7.5（RIG-I缺陷型）细胞在不同感染复数下经SeV感染后的表达情况，于感染后48小时完成检测。
6E: 以2^dCt值表征的<i>GAPDH-SEV</i>（编码仙台病毒基因组RNA）表达水平，在HuH7与HuH7.5细胞系中检测，于感染后48小时完成检测。
6F: 以<i>INHBA</i>的表达倍数变化（以<i>GAPDH</i>标准化），对应HuH7.5.1细胞感染后72小时相对于未感染（uninfected，U.I.）细胞的检测结果。
图6G: 以<i>MX1</i>的表达倍数变化（以<i>GAPDH</i>标准化），对应HuH7.5.1细胞感染后72小时相对于未感染（U.I.）细胞的检测结果。
7A: 以2^dCt值表征的<i>Hprt-Inhba</i>表达水平，为甲型流感病毒PR/8（FLUAV PR/8）感染的小鼠在感染后72小时的肺组织检测结果。
p { margin-bottom: 0.25cm; direction: ltr; color: #000000; line-height: 115%; text-align: left; orphans: 2; widows: 2; background: transparent }
p.western { font-family: "Liberation Serif", serif; font-size: 12pt; so-language: en-GB }
p.cjk { font-family: "Noto Serif CJK SC"; font-size: 12pt; so-language: zh-CN }
p.ctl { font-family: "FreeSans"; font-size: 12pt; so-language: hi-IN }
7B: 以2^dCt值表征的<i>Hprt-Isg15</i>表达水平，为FLUAV PR/8感染的小鼠在感染后72小时的肺组织检测结果。

7C: FLUAV PR/8感染的小鼠在感染后72小时的肺组织中，<i>Inhba</i>与<i>Isg15</i>转录本诱导水平的相关性分析（线性回归，R²=0.9271，p=0.002）
7D: 以2^dCt值表征的<i>Hprt-Inhba</i>表达水平，为FLUAV PR/8感染的小鼠在感染后72小时的肝脏组织检测结果。

7E: 以2^dCt值表征的<i>Hprt-Isg15</i>表达水平，为FLUAV PR/8感染的小鼠在感染后72小时的肝脏组织检测结果。
7F: 以2^dCt值表征的<i>Hprt-Inhba</i>诱导水平，为FLUAV PR/8感染的小鼠在感染后48小时的肺组织检测结果，覆盖递增范围的感染复数。

7G: 以2^dCt值表征的<i>Hprt-Inhba</i>表达水平，为野生型或MAVS敲低小鼠在感染FLUAV PR/8后48小时的检测结果。
7H: 以2^dCt值表征的<i>Hprt-Isg15</i>表达水平，为野生型或MAVS敲低小鼠在感染FLUAV PR/8后48小时的检测结果。
补充图1A: 以<i>INHBA</i>的表达倍数变化（以<i>GAPDH</i>标准化），对应HuH7细胞暴露于重组干扰素（IFN）或对照培养基（D10）后的检测结果。
补充图1B/C/D: OR6细胞在递增剂量的激活素A（activin A）存在下，用梯度稀释的IFNα进行孵育，检测海肾荧光素酶（Renilla luciferase）与Cell Titer Glo活性。